Myeloperoxidase Antibodies, IgG, Serum
Use
Evaluates patients with clinical features of anti-neutrophil cytoplasmic antibody-associated vasculitis, such as granulomatosis with polyangiitis and microscopic polyangiitis (MPA). It helps distinguish between MPA and other forms of ANCA-associated vasculitis when used in conjunction with proteinase 3 antibody and cytoplasmic neutrophil antibody testing. The test is also useful for following treatment response or monitoring disease activity in patients with myeloperoxidase (MPO) antibodies.
Special Instructions
Not provided.
Limitations
Positive results for MPO-ANCA or PR3-ANCA through either immunofluorescence or antigen-specific immunoassay must be interpreted with caution and within the clinical context. Negative results do not entirely exclude the diagnosis of ANCA-associated vasculitis due to potential variability in antibody levels or presence that fall below detection thresholds. Continuous monitoring of antibody levels should not solely be relied upon for treatment response evaluation or the prediction of disease activity and flare risk. Interpretation of results should also consider potential interfering factors such as specimen mis-handling or other technical variables.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Flow Immunoassay)
Biomarkers
Myeloperoxidase Antibodies
Antibody
LOINC Codes
- 48404-8 - Myeloperoxidase IgG Ser-aCnc
- 48404-8 - Myeloperoxidase IgG Ser-aCnc
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.35 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |